Cargando…
IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro
The ongoing pandemic spread of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) demands skillful strategies for novel drug development, drug repurposing and cotreatments, in particular focusing on existing candidates of host-directed antivirals (HDAs). The developmental drug IMU...
Autores principales: | Hahn, Friedrich, Wangen, Christina, Häge, Sigrun, Peter, Antonia Sophia, Dobler, Gerhard, Hurst, Brett, Julander, Justin, Fuchs, Jonas, Ruzsics, Zsolt, Überla, Klaus, Jäck, Hans-Martin, Ptak, Roger, Muehler, Andreas, Gröppel, Manfred, Vitt, Daniel, Peelen, Evelyn, Kohlhof, Hella, Marschall, Manfred |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762174/ https://www.ncbi.nlm.nih.gov/pubmed/33291455 http://dx.doi.org/10.3390/v12121394 |
Ejemplares similares
-
Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects
por: Muehler, Andreas, et al.
Publicado: (2020) -
Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases
por: Muehler, Andreas, et al.
Publicado: (2020) -
The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study
por: Muehler, Andreas, et al.
Publicado: (2019) -
Methodological Development of a Multi-Readout Assay for the Assessment of Antiviral Drugs against SARS-CoV-2
por: Hahn, Friedrich, et al.
Publicado: (2021) -
The Trimeric Artesunate Analog TF27, a Broadly Acting Anti-Infective Model Drug, Exerts Pronounced Anti-SARS-CoV-2 Activity Spanning Variants and Host Cell Types
por: Hahn, Friedrich, et al.
Publicado: (2022)